|
(-)-menthol 1-propylene glycol carbonate
|
DB14136 |
|
|
Hypochlorous acid
|
DB14135 |
[An oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.] |
|
Tallimustine
|
DB15466 |
[Tallimustine, a benzoyl mustard derivative of distamycin A, is an alkylating agent that binds to the minor groove of DNA.[A182036,A182039] It's association with severe myelotoxicity lead to the end of its development in favour of α-halogenoacrylamide derivatives such as [brostallicin], which have a favourable cytotoxicity/myelotoxicity ratio.[A182039,A182045] Newer generations of DNA minor groove binding agents can more specifically recognize base pair sequences.[A182051]] |
|
Yersinia pestis 195/p antigen (formaldehyde inactivated)
|
DB15461 |
[Yersinia pestis 195/p antigen (formaldehyde inactivated) is under investigation in clinical trial NCT02596308 (Immunogenicity and Safety of Subunit Plague Vaccine).] |
|
Methyl salicylate 2-ethylbutyrate
|
DB14130 |
|
|
AGG-523
|
DB15460 |
[AGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects with osteoarthritis).] |
|
8-chlorotheophylline
|
DB14132 |
[8-Chlorotheophylline is a stimulant drug of the xanthine chemical class, with physiological effects similar to caffeine. Its main use is in combination with [Diphenhydramine] as the antiemetic drug [Dimenhydrinate]. The stimulant properties of 8-chlorotheophylline are thought to ward off the drowsiness caused by diphenhydramine's anti-histamine activity in the central nervous system.
8-chlorotheophylline produces a number of effects including nervousness, restlessness, insomnia, headache, and nausea, which are primarily attributed to its ability to block the adenosine receptor [A33889, A1539]. Because adenosine causes a decrease in neuronal firing, blockade of the adenosine receptor causes the reverse effect resulting in excitation.] |
|
PT2977
|
DB15463 |
[PT2977 is an HIF-2α inhibitor. A kidney cancer treatment, it is the lead candidate drug for Peloton. Peloton was acquired by Merck & Co Inc on May 21, 2019.] |
|
Fucoxanthin
|
DB15462 |
[Fucoxanthin is under investigation in clinical trial NCT03613740 (Effect of Fucoxanthin on the Components of the Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion).] |
|
Basic Fibroblast Growth Factor
|
DB14131 |
[Basic Fibroblast Growth Factor (bFGF) is a single-chain polypeptide growth factor that plays a significant role in the process of wound healing and is a potent inducer of physiologic angiogenesis. Several different forms of the human protein exist ranging from 18-24 kDa in size due to the use of alternative start sites within the fgf-2 gene. It has a 55 percent amino acid residue identity to Fibroblast Growth Factor 1 and has potent heparin-binding activity. The growth factor is an extremely potent inducer of DNA synthesis in a variety of cell types from mesoderm and neuroectoderm lineages. It was originally named basic fibroblast growth factor based upon its chemical properties and to distinguish it from acidic fibroblast growth factor (Fibroblast Growth Factor 1). Although it is not approved for use in Canada or the USA, bFGF is currently undergoing investigation in a number of clinical trials.] |
|
(2S,3S,4R,5S)-2-(4-Amino-4,5-dihydro-1H-pyrrolo[3,2-d]pyrimidin-7-yl)-5-[(methylsulfanyl)methyl]-3,4-pyrrolidinediol
|
DB02158 |
|
|
2-Keto-3-Deoxygluconate
|
DB03489 |
|
|
(R)-Propylene glycol
|
DB02159 |
[A clear, colorless, viscous organic solvent and diluent used in pharmaceutical preparations.] |
|
Sulfopyruvate
|
DB02156 |
|
|
(S)-Aspartimide
|
DB03487 |
|
|
Uridine-5'-diphosphate-2-deoxy-2-fluoro-alpha-D-galactose
|
DB03488 |
|
|
Alpha-D-Fucose
|
DB03485 |
|
|
2,3-Bis-Benzo[1,3]Dioxol-5-Ylmethyl-Succinic Acid
|
DB02154 |
|
|
Phosphomethylphosphonic acid guanosyl ester
|
DB03486 |
|
|
3-[(3-sec-butyl-4-hydroxybenzoyl)amino]azepan-4-yl 4-(2-hydroxy-5-methoxybenzoyl)benzoate
|
DB02155 |
|
